Launch Drugs that Outperform the Competition
Research by biopharmaceutical\benchmarking leader Best Practices, LLC, hasfound that best-in-class firms focus more marketing resources on the earlystages of development in an effort to have a clearer picture of themarketplace.
"Companies need a clear game plan long before they start to put a launchplan into place," said Cameron Tew, senior manager of research and publishingat Best Practices, LLC. "That is why early marketing insights are so critical.These insights allow product teams to achieved faster and higher sales uptakeby ensuring that new products get appropriate resources committed at the righttime."
The 169-page report, "Launching Pharmaceutical Megabrands: Best Practicesin Marketing Blockbusters," includes 96 best practices drawn from surveys andinterviews with 24 executives at more than 15 leading pharmaceutical andbiotechnology companies such as Pfizer, Merck, Sanofi-Aventis,GlaxoSmithKline, Eli Lilly, Amgen, Boehringer-Ingelheim and Novartis.
For a complimentary download of a study excerpt, visithttp://www3.best-in-class.com/rr911.htm .
Marketing and branding decision-makers can use the report to gatherinsights on development topics ranging from marketing investment and expensepatterns to thought leader development for high-potential products. Inaddition, the report includes marketing success stories for 16 of the world'stop selling drugs.
To learn more about this study, review a complimentary report summary athttp://www3.best-in-class.com/rr911.htm .
To drill down on the metrics and best practices presented in this report,contact Cameron Tew at 919-767-9246 or email@example.com.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a research and consulting firm that conducts workbased on the principle that organizations can chart a course to superioreconomic performance by studying the best business practices, operatingtactics and winning strategies of world-class companies. For more information,call (919) 403-0251 or visit www.best-in-class.com.Some of the study findings include: -- Companies that consistently launch blockbuster drugs foster a culture that actively supports productive medical and marketing collaborations. -- Top-performing benchmark partners conduct a wide spectrum of market research, from pre-clinical to post-launch. -- Leading companies spend gradually and selectively on high impact pre- marketing activities to create awareness, demand and preferences for their new products.
SOURCE Best Practices, LLC
You May Also Like